United Arab Emirates: Digital Health Technology: A New Year And New FDA Guidance

Last Updated: 2 March 2018
Article by Hope S. Freiwald, Erik Snapp and Mary H. Kim

Digital health technology encompasses a variety of innovative healthcare tools including clinical decision support (CDS) and patient decision support (PDS) technology. These terms are used loosely to cover everything from a proprietary algorithm recommending optimal cancer therapies for individual patients to an app that relies on published guidelines to encourage physical activity. Some digital health products stand alone while others are accessories to conventional medical devices. As companies from Apple and Google to garage start-ups look to enter the health technology space with a broad range of medical software innovations, there are many questions related to which products will be regulated by FDA as medical devices and to what degree.

FDA has recognized the need for guidance in this area since at least 2011, and has slated digital health technology as a top priority since 2015. See FDA, Public Workshop – Mobile Medical Applications Draft Guidance; FDA, CDRH Fiscal Year 2015 (FY 2015) Proposed Guidance Development and Focused Retrospective Review of Final Guidance. But little has happened and many in industry have complained that the lack of clear regulatory guidance has hindered innovation that could benefit doctors and patients.

On December 8, 2017, FDA provided some greater clarity, issuing two draft and one final guidance. The final guidance adopts a set of principles and terminology agreed upon by an international group of medical device regulators. The two draft guidances, which are the primary focus of this article, address some of the issues left unresolved by the December 13, 2016 passage of the 21st Century Cures Act. Section 3060(a) of the Cures Act, which amended the FD&C Act to add Section 520(o), excluded certain software functions from the definition of a medical device that would be regulated by FDA. It also left substantial room for interpretation and further uncertainty.

FDA’s Function-Based Approach

The two draft guidances, “Changes to Existing Medical Software Policies Resulting from Section 3060 of the 21st Century Cures Act” (hereinafter “Draft Guidance on Changes to Medical Software Policies”), and “Clinical and Patient Decision Support Software” (hereinafter “Draft Guidance on Decision Support Software”), reflect FDA’s current thinking and recommendations for how industry may better interpret the language of the FD&C Act regarding the exclusion and inclusion of certain software functions. The first draft guidance clarifies the Agency’s interpretation of Section 520(o)(1)(A)-(D) of the FD&C Act, which discusses products with different functionality, including most significantly products for “maintaining or encouraging a healthy lifestyle.” See Draft Guidance on Changes to Medical Software Policies at 5. The second draft guidance provides greater insight to FDA’s thinking on Section 520(o)(1)(E) of the FD&C Act, which excludes from the definition of a device certain products that may be used by both healthcare providers and patients in making healthcare decisions.

Clarifying how Section 520(o)(1)(B) affects FDA’s existing General Wellness guidance, the first draft guidance states that a product will not be a medical device if it is only for encouraging or maintaining a general state of good health or a healthy lifestyle, presents a low safety risk and is not “related to the diagnosis, cure, mitigation, prevention or treatment of a disease or condition.” See Draft Guidance on Changes to Medical Software Policies at 8; see also Guidance on General Wellness: Policy for Low Risk Devices, issued July 29, 2016. In other words, an app on a watch that helps track energy consumption or output or recommends better dietary choices is not a medical device. Where, however, the software product relates a healthy lifestyle or healthy activities to something like lowering the risk of diabetes or heart disease, it is. Products that offer advice or conclusions on how healthy lifestyle choices may impact lifestyle diseases are medical devices as they are technically “related to the diagnosis, cure, mitigation, prevention or treatment of a disease or condition.” See Draft Guidance on Changes to Medical Software Policies at 8. Notwithstanding the categorization of these products as devices, however, FDA states that it intends to refrain from exercising its enforcement authority in this area, provided that the technology is low risk.

The second draft guidance provides greater insight to FDA’s thinking regarding FD&C Section 520(o)(1)(E), which excludes from the definition of device a CDS product that: (1) is not intended to take or analyze a medical image or signal (such as an MRI or ECG machine); (2) is intended to display patient or general medical information (such as practice guidelines); (3) is intended to provide recommendations for healthcare professionals; and (4) is intended to have the healthcare professional exercise his or her independent medical judgment about a specific patient without primarily relying on the CDS. See Draft Guidance on Decision Support Software at 5. The guidance also notes that PDS software with similar functionality and limitations—such as an app that helps patients know how to dose a medication consistent with its approved labeling—will not trigger FDA oversight. It also lists numerous examples of exempt and non-exempt products.

As with healthy lifestyle products, the regulatory lines are drawn mostly on functionality. If the CDS software uses publicly available information, applies that information to existing patient-specific data to recommend a diagnosis or treatment option, but leaves any final clinical decision to the individual healthcare provider, it is likely to be exempt. For PDS, the test is similar with the main difference being that the recommendation has to be one a patient could appropriately follow without expert medical consultation. In other words, software that lets doctors and patients make the kinds of healthcare decisions they have always made, but with potentially faster and more complete access to accepted relevant data via an electronic tool, will not be considered a medical device.

A Good Step – But What’s Next?

Most of the public reaction to the draft guidances thus far has been positive, viewing them as a step towards a regulatory approach that balances the need for potentially useful technological innovation with concern for patient safety and preservation of the doctor’s central role in medical decision-making. Some commentators, however, have suggested FDA has not been sufficiently nuanced in its approach and has failed to draw other potentially helpful lines.

Some have asked why FDA’s lines do not depend more on the seriousness of the disease or the degree of patient risk that could flow from the software’s recommendation. Should an app that recommends an optimal chemotherapeutic choice (even if using established guidelines) be treated the same as an app that recommends an optimal allergy medication?

Also, one may question the implications of FDA treating general wellness products as devices if they tie lifestyle choices to disease risks, but at the same time declining to use its regulatory authority over those devices. Will this create a more certain or less certain environment for innovation? And will it be a good result or not-so-good result for public health?

Another question relates to whether the complexity of the dataset and the methods for distilling information from it should be more important regulatory considerations than whether the data are publicly available. For example, two products may both rely on public information, but the one that uses only approved product labeling and practice guidelines may be a very different type of tool in the hands of a physician from the one that aggregates and wrests conclusions from various clinical and observational data. Will the physician truly have transparency regarding and be able to independently understand all of the published data utilized, when the data are updated, or how the algorithms are analyzing, weighing and interpreting the data? On the other hand, is this materially different from the current imperfect system where many clinicians likely do not have time or ability to fully review and digest the published literature?

FDA’s thinking on exempt versus non-exempt products also depends heavily on whether they dictate or merely “recommend” a course of action to the learned intermediary. But the fact that a product is characterized as making only a recommendation, which may be accepted or rejected by the healthcare provider, does not entirely predict how it will be used in clinical practice. Will the learned intermediary still exercise the same level of independent clinical judgment when faced with a technology-driven guide that is potentially part of the patient’s record? And will any shift, on balance, be good for patients?

Out of the Frying Pan and into the Fire?

For those thinking about business risks for innovators in this area, it should also be clear that a more hands-off regulatory scheme could mean greater litigation risks in the form of consumer fraud, false advertising or other claims. Just because a product with a healthy lifestyle purpose is not FDA-regulated does not make it any less vulnerable to the same kinds of claims facing manufactures of supplements, foods, and other consumer products, whose claimed benefits are often the subject of litigation challenges. In fact, less regulation may bring even greater litigation risks.

One may also imagine a host of litigation pitfalls related to product disclosures and warnings. For example, will there be lawsuits claiming that in the absence of greater regulatory oversight, doctors were not able to fully understand the strengths and limitations of new tools?

Even with unanswered questions, the use and advancement of technology in the field of digital health show no signs of slowing down. The new FDA draft guidance documents help cement and solidify the existence of CDS and PDS software as important tools in medicine. To harness the full potential this field has to offer, the industry should continue to ask questions and encourage discussion in an ever-changing era of digital health. The public comment period for the draft guidance documents closes on February 6, 2018.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions